StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology r&d expenses

Research and development expenses are spending on new products and technology.

Puma Biotechnology's R&D Expenses for the twelve months ending Jun 30, 2026 was $71.44M, up 25.3% year over year. For fiscal 2025 it was $62.07M, up 13.0% from the year before. Over ten years it grew -11.4% a year on average. The highest annual figure on record is $222.80M in fiscal 2016.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$62.07M+13.0%
FY2024Dec 31, 2024$54.94M+9.0%
FY2023Dec 31, 2023$50.38M-3.6%
FY2022Dec 31, 2022$52.24M-27.3%
FY2021Dec 31, 2021$71.87M-26.4%
FY2020Dec 31, 2020$97.65M-26.5%
FY2019Dec 31, 2019$132.85M-19.4%
FY2018Dec 31, 2018$164.85M-20.7%
FY2017Dec 31, 2017$207.81M-6.7%
FY2016Dec 31, 2016$222.80M+6.9%
FY2015Dec 31, 2015$208.47M+69.6%
FY2014Dec 31, 2014$122.92M+172.9%
FY2013Dec 31, 2013$45.05M-9.2%
FY2012Dec 31, 2012$49.64M+5909.2%
FY2011Dec 31, 2011$826.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$18.90M+22.3%
Q1 FY2026Mar 31, 2026$19.80M+42.8%
Q4 FY2025Dec 31, 2025$16.84M+11.0%
Q3 FY2025Sep 30, 2025$15.91M+26.8%
Q2 FY2025Jun 30, 2025$15.45M+13.4%
Q1 FY2025Mar 31, 2025$13.86M+2.0%
Q4 FY2024Dec 31, 2024$15.17M+17.8%
Q3 FY2024Sep 30, 2024$12.55M+9.6%
Q2 FY2024Jun 30, 2024$13.63M+2.1%
Q1 FY2024Mar 31, 2024$13.59M+6.9%
Q4 FY2023Dec 31, 2023$12.87M-6.6%
Q3 FY2023Sep 30, 2023$11.45M+1.7%
Q2 FY2023Jun 30, 2023$13.36M+11.6%
Q1 FY2023Mar 31, 2023$12.71M-16.6%
Q4 FY2022Dec 31, 2022$13.78M-2.7%
Q3 FY2022Sep 30, 2022$11.25M-40.3%
Q2 FY2022Jun 30, 2022$11.97M-35.8%
Q1 FY2022Mar 31, 2022$15.24M-24.7%
Q4 FY2021Dec 31, 2021$14.17M-41.4%
Q3 FY2021Sep 30, 2021$18.84M-19.3%
Q2 FY2021Jun 30, 2021$18.64M-24.5%
Q1 FY2021Mar 31, 2021$20.23M-20.5%
Q4 FY2020Dec 31, 2020$24.16M-20.1%
Q3 FY2020Sep 30, 2020$23.34M-22.3%
Q2 FY2020Jun 30, 2020$24.69M-33.0%
Q1 FY2020Mar 31, 2020$25.46M-28.8%
Q4 FY2019Dec 31, 2019$30.24M-21.1%
Q3 FY2019Sep 30, 2019$30.03M-17.4%
Q2 FY2019Jun 30, 2019$36.86M-14.8%
Q1 FY2019Mar 31, 2019$35.73M-23.9%
Q4 FY2018Dec 31, 2018$38.33M-23.7%
Q3 FY2018Sep 30, 2018$36.36M-26.5%
Q2 FY2018Jun 30, 2018$43.25M-18.8%
Q1 FY2018Mar 31, 2018$46.93M-14.4%
Q4 FY2017Dec 31, 2017$50.25M-10.9%
Q3 FY2017Sep 30, 2017$49.50M-4.8%
Q2 FY2017Jun 30, 2017$53.25M–
Q1 FY2017Mar 31, 2017$54.80M–
Q4 FY2016Dec 31, 2016$56.40M–
Q3 FY2016Sep 30, 2016$51.98M–

More Puma Biotechnology figures

See a number that looks wrong?